Clincosm LogoSign in Get a demo

Prevalence of Thrombosis in COVID-Patients

Sponsor
University Hospital Augsburg (Other)
Overall Status
Completed
CT.gov ID
NCT04615026
Collaborator
(none)
525
Enrollment
1
Location
7.8
Actual Duration (Months)
67.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: duplex sonography

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
525 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity
Actual Study Start Date :
Nov 4, 2020
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
COVID 19 patients

all patients with positive SARS-CoV 2 swap

Diagnostic Test: duplex sonography
all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
Other Names:
  • test of smell
  • cognitive test
  • blood sample

    		•

    Outcome Measures

    Primary Outcome Measures

    1. prevalence of thrombosis [20 minutes]

    Secondary Outcome Measures

    1. correlation to immunity [20 minutes]

    2. Assessment of late complications [20 minutes]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • SARS CoV 2 positive swap, at least 4 weeks after infection
    Exclusion Criteria:
    • under 18 years old no consent anemia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Augsburg Augsburg Germany 86165

    Sponsors and Collaborators

    • University Hospital Augsburg

    Investigators

    • Principal Investigator: Alexander Hyhlik-Duerr, MD, University Hospital Augsburg

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alexander Hyhlik-Dürr, Head of department, University Hospital Augsburg
    ClinicalTrials.gov Identifier:
    NCT04615026
    Other Study ID Numbers:
    • COVID Thrombose
    First Posted:
    Nov 4, 2020
    Last Update Posted:
    Jun 2, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Thrombosis

    Study Results

    No Results Posted as of Jun 2, 2022